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be helped by the introduction of high-throughput 
multiplex genotyping, which will enable simultaneous 
sequencing and measuring copy numbers of hundreds 
of genes from only nanograms of cancer cell DNA.
Although these advances will probably reduce the 
proportion of patients who need chemotherapy, it will 
remain the main treatment option for advanced NSCLC. 
The TAILOR study will contribute to more rational use 
of chemotherapy and EGFR tyrosine kinase inhibitors in 
the treatment of NSCLC, based on its molecular proﬁ le.
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Combination endocrine treatments unproven in breast cancer
Ovarian ablation, which was introduced more than 
100 years ago, was the ﬁ rst endocrine treatment for 
advanced breast cancer, followed by adrenalectomy and 
hypophysectomy. These ablative therapies have since 
been replaced by antioestrogen treatments, luteinising-
hormone-releasing hormone agonists, and aromatase 
inhibitors.1 Other endocrine treatments  with diﬀ erent 
mechanisms of action have also become available 
for breast cancer: oestrogens, progestins, androgens, 
antiandrogens, and selective oestrogen-receptor 
downregulators. 
Although the superiority of combinations of 
chemotherapeutic agents with diﬀ erent mechanisms 
of action to single agents has been established in 
the treatment of early and advanced breast cancer,2 
that of combinations of endocrine treatments has 
not been shown.1 Several combinations of hormonal 
agents have been assessed in patients with advanced 
breast cancer, with no consistent improvement in 
either time to progression of disease or survival.3 
Additionally, the combination of an antioestrogen 
treatment (tamoxifen) and ovarian suppression with 
a luteinising-hormone-releasing hormone agonist 
does not lead to improvements in disease-free or 
overall survival when compared with antioestrogen 
treatment alone in premenopausal women with early 
breast cancer.4 A large, prospective, double-blind trial5 
comparing tamoxifen with an aromatase inhibitor 
(anastrozole) and tamoxifen or anastrozole alone as 
adjuvant treatment for breast cancer showed that the 
combination did not improve either disease-free or 
overall survival. Indeed, the group who received the 
combination was discontinued after initial analysis of 
the data.5
Because preclinical data6 suggested that the 
combination of an aromatase inhibitor and 
fulvestrant—a member of the newest class of hormonal 
agents, selective oestrogen receptor downregulators—
was superior to either agent alone against breast 
tumours in mice, three prospective studies7–9 have 
assessed this approach in postmenopausal women 
with advanced breast cancer. In The Lancet Oncology, 
Stephen Johnston and colleagues report results of a 
phase 3, European, multicentre trial.7 Postmenopausal 
women with hormone-receptor-positive breast cancer 
who had relapsed or progressed while receiving a non-
steroidal aromatase inhibitor were randomly assigned 
to receive fulvestrant plus anastrozole, fulvestrant plus 
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anastrozole-matched placebo, or the steroidal aromatase 
inhibitor exemestane. No improvement in progression-
free survival was recorded in the group who received 
fulvestrant plus anastrozole (median 4·4 months, 
95% CI 3·4–5·4) compared with fulvestrant plus placebo 
(4·8 months, 3·6–5·5; hazard ratio [HR] 1·00, 95% CI 
0·83–1·21; log-rank p=0·98), or in the group given 
fulvestrant plus placebo compared with exemestane 
(3·4 months, 3·0–4·6; HR 0·95, 0·79–1·14; log-rank 
p=0·56). 
Another phase 3 study8 comparing the combination 
of anastrozole and fulvestrant as ﬁ rst-line treatment 
in postmenopausal patients with hormone-receptor-
positive advanced breast cancer also showed no 
advantages in terms of clinical eﬃ  cacy for the 
combination compared with anastrozole alone. 
By contrast, a phase 3 trial from North America9 
compared the combination of anastrozole and 
fulvestrant with anastrozole alone as ﬁ rst-line 
treatment in postmenopausal women with hormone-
receptor-positive advanced breast cancer, and showed 
increased control of disease and survival with the 
combination of fulvestrant and anastrozole. However, 
the apparent improvements could have been due to 
imbalances in prognostic characteristics between the 
two study groups. 
Therefore, there are still no consistent data to support 
the notion that combination endocrine therapy is 
superior to treatment with one agent in early or 
advanced breast cancer. However, as understanding of 
the mechanisms of resistance to endocrine treatment 
has improved, targeting of some pathways has resulted 
in new approaches that oﬀ er hope for disease control. 
For example, postmenopausal patients with hormone-
receptor-positive, HER2-positive advanced breast 
cancer given endocrine and anti-HER2 treatments have 
had longer control of disease than have those given 
endocrine treatment alone.1 Indeed, a combination of 
an aromatase inhibitor with an anti-HER2 treatment has 
been approved by the US Food and Drug Administration 
for the management of postmenopausal patients with 
hormone-receptor-positive, HER2-positive advanced 
breast cancer.1 Another eﬀ ective approach has been the 
combination of an mTOR inhibitor (everolimus) with 
exemestane.10 The combination of exemestane with a 
histone deacetylase inhibitor (entinostat) has also had 
encouraging results.11
In conclusion, a combination of endocrine agents 
with diﬀ erent mechanisms of action will probably 
not result in a meaningful improvement in outcomes 
for patients with breast cancer. Sequential use of 
endocrine agents remains the standard of care in 
patients with advanced breast cancer. However, 
understanding of the mechanisms of resistance 
to hormonal agents continues to advance, and 
combinations of endocrine treatment with targeted 
agents that block resistance pathways should improve 
the outlook for patients with breast cancer that is 
resistant to endocrine treatment.
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